IGI Logo

Below are Quote on Cipla launched Casirivimab and Imdevimab, another drug to fight against Covid 19 in India by Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd   

Cipla Limited in partnership with Roche India launch first batch of Antibody Cocktail (Casirivimab and Imdevimab) to fight against covid 19 in India, Casirivimab and Imdevimab is indicated for restricted use in emergency situation for the treatment of mild to moderate COVID-19 in patients who are at high risk of severe COVID19.

Cipla expects the first batch to benefit 200000 patients in India and second phase to come in Mid of June 2021.

This is very positive news for the Cipla limited while this will help to bring down the death rate in India. Cipla already launched more than 10 products in India related to covid 19 treatment.

Cipla priced this drug at ₹59750 for both the drugs which will be used for one patient. We expect this will help cipla to increase domestic revenue by 500-800 Cr approximately in Q1FY2021 anlong with this it will be a higher margin product for the company.